Sagenex SRL
1.1 FTESagenex reported total assets of 73,820 € at the end of the 2025 financial year (annual accounts filed with the NBB on 20 Jul 2026), with 1.1 full-time equivalent.
The score of Sagenex shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -43 % Headcount (avg FTE) -61 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Sagenex's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Jul 2026
- Year ended 31 Dec 2024filed on 15 Jul 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Sagenex's financial analysis
- Solvency19.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Sagenex
Sagenex's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0460.691.897
- VAT number
- BE0460691897
- Peppol
- Registered · 0208:0460691897 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 May 1997
- Registered office
- 5000 Namur
- Size
- Micro · 1.1 FTE
- Latest accounts
- 2025 · filed on 20 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Sagenex (SRL) has been based in Namur since 1997, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 13,637 € and equity of 14,359 €; its revenue is not published. With 1.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 19.5%, below the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Sagenex
Companies in the same business, of comparable size and area, outside its group.
- Sirrah Retail sale of pharmaceutical products Tournai · balance sheet 84,897 €
- Arkophar Retail sale of pharmaceutical products Zutendaal · balance sheet 73,718 €
- Arucarea Retail sale of pharmaceutical products Oud-Turnhout · balance sheet 73,983 €
- NED Pharma Retail sale of pharmaceutical products Mons · balance sheet 74,278 €
- Apotheker Van De Weghe Karen Retail sale of pharmaceutical products Sint-Martens-Latem · balance sheet 73,167 €
- Apr. ZEYREK Retail sale of pharmaceutical products Leuven · balance sheet 72,982 €
- ESPharma Retail sale of pharmaceutical products Anderlecht · balance sheet 74,825 €
- LouksPharma Retail sale of pharmaceutical products Fernelmont · balance sheet 72,654 €
Frequently asked questions about Sagenex
What is the revenue of Sagenex?
Sagenex files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Sagenex?
In Belgium, the VAT number is the company number prefixed with BE: BE0460691897 for Sagenex, if the company is VAT-registered. Its company number (CBE) is 0460.691.897.
Where is the registered office of Sagenex?
According to the CBE register, the registered office of Sagenex is in 5000 Namur.
What is the equity of Sagenex?
At the close of the 2025 financial year, the equity of Sagenex amounts to 14,359 €, a solvency of 19.5% of total assets.
How many people work at Sagenex?
1.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Sagenex?
The register lists 1 active mandates at Sagenex. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Sagenex
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →